Ligand Third Quarter 2026 Earnings Call - LIGAND PHARMACEUTICALS INC

Financial Performance:

• Royalty revenue reached $70.3 million in Q3 2026, a 51% year-over-year increase, driven by the Zoma acquisition and legacy portfolio momentum.
• Adjusted diluted EPS was $2.67, down from $3.09 in the prior year quarter which included $24.5 million in one-time outlicense income; GAAP net loss was $1.43 per share.
• Core cash operating expenses (non-GAAP) are on track at approximately $50 million for 2026, down from $92 million in 2022.
• Cash and equivalents stood at approximately $450 million; total deployable capital including equity and credit facilities is ~$750 million.
• Financial royalty assets balance increased from ~$200 million to $800 million post-Zoma acquisition, with revenue now recognized based on long-term cash flow forecasts rather than quarterly partner reports.
• Total core revenue was $78.7 million (down 9% YoY); excluding the $24.5 million Pelford's divestiture income, core revenue grew 26%.

Guidance and Future Outlook:

• Full-year 2026 adjusted diluted EPS guidance raised to $9.50–$9.75 (from $9.00–$9.50).
• 2026 Revenue guidance reaffirmed: Royalty revenue $225–$250M, Total revenue $270–$310M, CapEx revenue $35–$40M, Contract revenue $10–$20M.
• Revenue expected to be heavily weighted to Q4 due to a full quarter of Zoma royalties and tiered royalty rate structures stepping up later in the year.
• Management anticipates up to seven pivotal trial readouts by end of 2027, five stemming from the Zoma acquisition.
• Long-term growth strategy targets a 34% CAGR in royalty revenue and 41% CAGR in adjusted EPS from 2022 through mid-2026.
• A comprehensive five-year outlook update is scheduled for the December 8th Investor Day, factoring in the Zoma acquisition, Filspari approval, and Palvella's regulatory progress.

Business Segments and Product Lines:

• Commercial Assets: Filspari is the largest royalty asset at $16.8M (up 85% YoY), overtaking Kipralis; Ojemda, Otuver, and MyPlypha (from Zoma) each contributed ~$7M; Vilspari (Zilsuvmi) continued strong growth.
• Zoma Acquisition: Closed July 14, 2026, adding three commercial assets (Ojemda, Vibismo, MyPlypha) and 100+ pipeline programs; estimated contribution of $1.50 EPS to 2027 guidance.
• New Investments: Acquired royalty interest in Raijunia (Santén's pediatric myopia product) for $23M; invested in Avancel (CAR-T platform) with a $47M financing agreement including royalty and equity tranche.
• Pipeline Catalysts: Palvella's cuturam rapamycin received PDUFA date of Feb 28, 2027, for microcystic lymphatic malformations; Takeda assets mezogidamab and velixibet show strong Phase II/III progress with peak royalty estimates exceeding $30M–$45M each.
• Portfolio Size: Total commercial, clinical, and preclinical royalty assets now exceed 200.

Market and Competitive Landscape:

• Operating as a pure royalty aggregation model following the 2022 pivot, focusing on diversified, durable revenue streams across therapeutic areas.
• Deal flow remains robust: >180 opportunities reviewed in 2026, 115 confidentiality agreements signed (60% conversion rate), and six deals closed.
• Competition in commercial-stage royalty space is acknowledged as high, with Ligand targeting IRRs in the high teens to low 20s via special situations and structural advantages.
• Market trends favor late-stage clinical assets with high unmet medical need, leveraging Ligand's expanded deal team and systematic portfolio management.

Risks and Challenges:

• Timing Uncertainty: Customer order flows and regulatory milestone timing remain the most challenging variables for revenue guidance.
• Binary Risk: Pivotal trial readouts carry inherent success/failure risks, though the diversified portfolio (>200 assets) mitigates single-asset impact.
• Accounting Complexity: Revenue recognition for partners not yet reporting sales is based on estimates (sell-side consensus), subject to adjustment in the following quarter.
• Regulatory Risk: U.S. regulatory skepticism regarding Raijunia's US trial does not impact EU/UK approvals but requires monitoring for potential read-across risks.

Management Commentary and Tone:

• Tone was highly confident and optimistic, describing the period as the "most catalyst-rich" in the company's history.
• Management emphasized the successful integration of Zoma, noting cost synergies are slightly better than expected (targeting <5M annual incremental costs).
• CFO Tavo Espinoza noted a change in reporting timing to align with the new scale of financial royalty assets, improving forward-looking transparency.
• CEO Todd Davis highlighted the strategic shift to a capital-light model, having cut core OPEX by over $40M since 2022 while scaling the portfolio.

Analyst Questions and Answers:

• Hidden Gems in Zoma: Management confirmed significant option value is being uncovered in under-valued assets (e.g., Resolute/Locks), with follow-on capital capabilities enhancing success probabilities.
• Zoma EPS Contribution: No changes to guidance; Zoma expected to contribute $0.50 to 2026 EPS and $1.50 to 2027 EPS.
• Palvella/Cuturam: FDA priority review granted for Feb 2027; potential for sales in the hundreds of millions to $1B+ with tiered royalties up to 9.8%.
• Capital Deployment Pace: ~$200M deployed annually is sufficient to sustain growth through the mid-2030s; pace may accelerate with recent hiring of two new deal leads.
• Q4 Guidance Conservatism: Lower end of Q4 royalty guidance ($64–$89M implied) reflects caution pending final partner reporting and uncertainty in commercial order flows.
• Raijunia US/EU Dynamics: US regulatory issues are viewed as independent; no read-across risk to EU/UK commercialization or reimbursement.
• Synergies: Zoma transaction integration costs were one-time; ongoing G&A run rate post-synergies is projected to be < $5M incremental.

Other Key Points:

• Convertible Notes: $460M of 0.75% notes due 2030 and $700M of 0% notes due 2031 issued; dilution limited to warrants with strike prices of ~$294 and ~$524 respectively.
• Sotiksestat: Royalty interest revitalized after global rights were acquired by MyGand from Takeda; demonstrates the flexibility of royalty investing as assets change hands.
• Amedica/Ganoxalone: Partner Amedica advancing Phase III study for refractory status epilepticus in 2027, building on prior Marinus acquisition.
  Reporting Change: First quarter of 2026 marks a shift in earnings release timing to align with the accelerated recognition of financial royalty income.